Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma
2018
Abstract not available. Disclosures: Study sponsored by Novartis. Copyright 2018 SKIN
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI